XOMA News and Press, XOMA Corporation From 03/10/20

XOMA (NASDAQ: XOMA ): Q4 GAAP EPS of -$0.49 misses by $0.21 . More news on: XOMA Corporation, Earnings news and commentary, Healthcare stocks news, , Read more ...

Added more than 20 new partner-funded programs in 2019 with potential for milestone and royalty payments  Received $15.8 million from partners during the year  Current cash balance sufficient to fund operations for multiple years EMERYVILLE, Calif., March 10, 2020 (GLOBE N...

XOMA ( XOMA   -7% ) will collaborate with Zydus Cadila to develop an immuno-oncology drug candidate the combines the latter's IL-2 with XOMA's anti-IL-2 monoclonal antibody. More news on: XOMA Corporation, Healthcare stocks news, Stocks on the move, Read more ...

AHMEDABAD, India and EMERYVILLE, Calif., March 09, 2020 (GLOBE NEWSWIRE) -- Zydus Cadila, an innovation-driven global pharmaceutical company, and XOMA Corporation (Nasdaq: XOMA) today announced they have entered into a licensing agreement to advance an IL-2-based immuno-oncology (IO) drug c...

A Little About Me I can remember when I was young and healthy and had no cancer issues or extended hospital stays and no serious surgeries! I was an optimist about everything, including the stock market - especially when it came to dividend growth investing. Invest for the long term, ge...

EMERYVILLE, Calif., Feb. 25, 2020 (GLOBE NEWSWIRE) -- XOMA Corporation (NASDAQ: XOMA) announced today its Chief Executive Officer, Jim Neal, will present an update about the Company’s business at the Cowen and Company 40 th Annual Health Care Conference in Boston, Massachusetts. &#x...

Written by Danny Cohen and Scott Matusow We have identified Five Prime Therapeutics ( FPRX ) as a potential turn-around story with upcoming pivotal data, an activist biotech fund with nearly 22% ownership, and important business decisions this year than can make this company a very l...

EMERYVILLE, Calif., Dec. 20, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced the closing of its previously announced rights offering (the “Rights Offering”).  At the closing, XOMA sold and issu...

EMERYVILLE, Calif., Dec. 05, 2019 (GLOBE NEWSWIRE) -- As part of its R&D Day on December 5, 2019, Novartis highlighted the progress that has been made on iscalimab (CFZ533), a product candidate, for which XOMA (NASDAQ: XOMA) has the potential to earn royalties that are tiered from a mid...

EMERYVILLE, Calif., Dec. 02, 2019 (GLOBE NEWSWIRE) -- XOMA Corporation (Nasdaq: XOMA) (“XOMA” or the “Company”) today announced it has commenced the previously announced rights offering to raise gross proceeds of approximately $22 million (the “Rights...